Stay updated on Pembrolizumab & Bavituximab in Advanced HCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Bavituximab in Advanced HCC Clinical Trial page.

Latest updates to the Pembrolizumab & Bavituximab in Advanced HCC Clinical Trial page
- Check7 days agoChange DetectedThe webpage has undergone significant updates, including the addition of a new study on Hepatocellular Carcinoma (HCC) and the involvement of collaborators such as Merck Sharp & Dohme LLC. Additionally, the revision number has been updated to v2.15.0.SummaryDifference65%
- Check14 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check22 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check29 days agoNo Change Detected
- Check58 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1.0%
- Check72 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1.0%
- Check79 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab & Bavituximab in Advanced HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Bavituximab in Advanced HCC Clinical Trial page.